Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | REM-422 |
Synonyms | |
Therapy Description |
REM-422 is an mRNA degrader targeting MYB, which induces nonsense-mediated decay of the MYB transcript and decreased Myb protein levels, potentially inhibiting tumor growth (Blood (2023)142 (Supplement 1): 1425). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REM-422 | REM 422|REM422 | REM-422 is an mRNA degrader targeting MYB, which induces nonsense-mediated decay of the MYB transcript and decreased Myb protein levels, potentially inhibiting tumor growth (Blood (2023)142 (Supplement 1): 1425). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06297941 | Phase I | REM-422 | Study of REM-422 in Patients With AML or Higher Risk MDS | Recruiting | USA | 0 |
NCT06118086 | Phase I | REM-422 | Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Recruiting | USA | 0 |